| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/20/2006 | US7063960 Interacting the immature dendritic cels with an antigen ex vivo so that the surface antigen is presented; inducing maturation ex vivo; and contacting with a modulator comprising TRANCE or derivative |
| 06/20/2006 | US7063954 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 06/20/2006 | US7063851 Herpes viruses for immune modulation |
| 06/20/2006 | US7063835 Virus strains |
| 06/15/2006 | WO2006063356A1 Regulation of epigenetic control of gene expression |
| 06/15/2006 | WO2006063252A2 Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas |
| 06/15/2006 | WO2006063247A2 Regulated expression of transgenes in the central nervous system of mammals |
| 06/15/2006 | WO2006063164A2 Compositions and methods for treating neuroendocrine tumors |
| 06/15/2006 | WO2006063128A2 Methods, assays and compositions for treating retinol-related diseases |
| 06/15/2006 | WO2006063082A2 Methods and compositions for modulating apoptotic pathways |
| 06/15/2006 | WO2006063009A2 Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on proteins differentially expressed in serum |
| 06/15/2006 | WO2006062946A2 Incorporation of bone marrow derived stem cells in tumors |
| 06/15/2006 | WO2006062817A2 Compositions and methods for the treatment of peripheral b-cell neoplasms |
| 06/15/2006 | WO2006062723A2 Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
| 06/15/2006 | WO2006062647A2 Gene expression and genetic changes implicated in alcoholism |
| 06/15/2006 | WO2006062596A2 RNAi MODULATION OF RSV, PIV AND OTHER RESPIRATORY VIRUSES AND USES THEREOF |
| 06/15/2006 | WO2006062402A2 Heat shock proteins (hsp) and supraventricular arrhythmia |
| 06/15/2006 | WO2006062369A1 Method of inhibiting expression of target mrna using sirna consisting of nucleotide sequence complementary to said target mrna |
| 06/15/2006 | WO2006062094A1 Novel cancer antigen peptide and the use thereof |
| 06/15/2006 | WO2006061824A2 Chondrocyte-based implant for the delivery of therapeutic agents |
| 06/15/2006 | WO2006060903A1 Signal peptides, nucleic acid molecules and methods of treatment |
| 06/15/2006 | WO2006060898A1 Method for treating inflammatory disorders |
| 06/15/2006 | WO2006050999A3 Methods of reducing body fat |
| 06/15/2006 | WO2006015389A3 Methods and compositions for enhancing the efficacy and specificity of rna silencing |
| 06/15/2006 | WO2006013013A3 Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb) |
| 06/15/2006 | WO2006010838A3 Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle |
| 06/15/2006 | WO2005123923A3 Inducer specific tetracycline repressor proteins and methods of use thereof |
| 06/15/2006 | WO2005123121A3 Use of dna molecule as vaccine adjuvant |
| 06/15/2006 | WO2005118824A9 Methods and compositions for the inhibition of gene expression |
| 06/15/2006 | WO2005118824A2 Methods and compositions for the inhibition of gene expression |
| 06/15/2006 | WO2005117993A3 Method of using adenoviral vectors with improved safety and efficacy for the treatment of cancer |
| 06/15/2006 | WO2005110494A3 Methods and compositions for the inhibition of thrombus formation |
| 06/15/2006 | WO2005110436A3 Macromolecule-containing sustained release intraocular implants and related methods |
| 06/15/2006 | WO2005079397A3 Anti-microrna oligonucleotide molecules |
| 06/15/2006 | WO2005005599A3 Modulation of c-reactive protein expression |
| 06/15/2006 | US20060130169 Transgenic non-human mammals that reproduce human pathologies of stem cell origins, such as chromosomal anomalies associated with chronic myeloid leukemia, B-cell acute lymphoblastic leukemia, T-cell acute or lymphoblastic leukemia, or with the migration of hematopoietic or embryonic stem calls. |
| 06/15/2006 | US20060130168 Using transgenic non-human mammals that reproduce human pathologies of stem cell origins, such as chromosomal anomalies associated with chronic myeloid leukemia, B-cell acute lymphoblastic leukemia, T-cell acute or lymphoblastic leukemia, or with the migration of hematopoietic or embryonic stem cells |
| 06/15/2006 | US20060130167 Transgenic non-human mammals as models for human pathologies of stem cell origin |
| 06/15/2006 | US20060130166 Transgenic non-human mammals as models for human pathologies of stem cell origin |
| 06/15/2006 | US20060130164 Toll/interleukin-1 receptor adapter protein (TIRAP) |
| 06/15/2006 | US20060128651 Methods and compositions for modulating drug activity through telomere damage |
| 06/15/2006 | US20060128650 Allele-specific RNA interference |
| 06/15/2006 | US20060128649 Aptamer-mediated regulation of gene expression |
| 06/15/2006 | US20060128648 Preparing a suppression effector and replacement nucleic acid that have modifications in one or more third base (wobble) positions so that replacement nucleic acids still code for the wild type or equivalent amino acids |
| 06/15/2006 | US20060128647 Novel oligonucleotides and treating cardiac disorders by using the same |
| 06/15/2006 | US20060128646 Antisense design |
| 06/15/2006 | US20060128645 Inhibition of proliferation and infiltration of brain tumor cells caused by expression of ampa-type glutamate receptor subunit |
| 06/15/2006 | US20060128644 Use of mob-5 in pain |
| 06/15/2006 | US20060128619 Therapeutic use of modulators of notch |
| 06/15/2006 | US20060128617 Oligoribonucleotide or peptidic nucleic acid inhibiting function of hepatitis c virus |
| 06/15/2006 | US20060128608 Novel chemical compounds and their use |
| 06/15/2006 | US20060127984 Modified Vaccinia virus Ankara for the vaccination of neonates |
| 06/15/2006 | US20060127980 Human excitatory amino acid transporter-2 gene promoter and uses thereof |
| 06/15/2006 | US20060127927 Mammalian IAP gene family, primers, probes, and detection methods |
| 06/15/2006 | US20060127909 Polynucleotides targeted against hter and use thereof |
| 06/15/2006 | US20060127895 Use of c-jun or c-jun activating agents such as uv or c-jun n-terminal kinases (junks) for treating cancer |
| 06/15/2006 | US20060127894 Protein associated with cell growth, differentiation, and death |
| 06/15/2006 | US20060127891 RNA interference mediated inhibition of MAP kinase gene expression or expression of genes involved in MAP kinase pathway using short interfering nucleic acid (siNA) |
| 06/15/2006 | US20060127890 Novel gene overexpressed in heart and skeletal muscle and use thereof |
| 06/15/2006 | US20060127873 Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors |
| 06/15/2006 | US20060127502 Methods for inhibiting Stat3 signaling in immune cells |
| 06/15/2006 | US20060127482 Combination of immuno gene therapy & chemotherapy for treatment of cancer & hyperproliferative diseases |
| 06/15/2006 | US20060127405 Specifically recognizing human oculospanin and having cytotoxic activity against cancer cells, cancer therapy |
| 06/15/2006 | US20060127402 Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors |
| 06/15/2006 | US20060127401 Screening method |
| 06/15/2006 | US20060127400 Activation of regulatory T cells by alpha-melanocyte stimulating hormone |
| 06/15/2006 | US20060127397 RAG polypeptides, nucleic acids, and their use |
| 06/15/2006 | US20060127391 Methods and materials for treating inflammatory conditions |
| 06/15/2006 | US20060127377 T cell receptors with enhanced sensitivity recognition of antigen |
| 06/15/2006 | US20060127376 Methods and compositions for modulating apoptotic pathways |
| 06/15/2006 | US20060127366 Method and device for inducing biological processes by micro-organs |
| 06/15/2006 | US20060127361 Compositions and methods for inducing gene expression |
| 06/15/2006 | US20060127360 Multi-antigen vectors of melanoma |
| 06/15/2006 | US20060127359 Methods and compositions for heat activated gene therapy using cytolethal distending toxin |
| 06/15/2006 | US20060127358 Raav expression systems and methods for enhancing transduction of mammalian neural cells |
| 06/15/2006 | US20060127312 Notch signaling in long-term memory formation |
| 06/15/2006 | CA2630088A1 Signal peptides, nucleic acid molecules and methods of treatment |
| 06/15/2006 | CA2600898A1 Novel cancer antigen peptide and the use thereof |
| 06/15/2006 | CA2593034A1 Compositions and methods based upon the kinase haspin |
| 06/15/2006 | CA2590061A1 Hsp and supraventricular arrhythmia |
| 06/15/2006 | CA2589406A1 Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas |
| 06/15/2006 | CA2587790A1 Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on proteins differentially expressed in serum |
| 06/15/2006 | CA2586690A1 Influenza vaccination |
| 06/15/2006 | CA2584309A1 Rnai modulation of rsv, piv and other respiratory viruses and uses thereof |
| 06/14/2006 | EP1669083A1 Heat shock proteins (HSP) and supraventricular arrhythmia |
| 06/14/2006 | EP1668144A2 Nucleotide sequences promoting the trans-membrane transport of nucleic acids |
| 06/14/2006 | EP1668143A2 Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| 06/14/2006 | EP1668120A2 Method for detecting cancer cells and monitoring cancer therapy |
| 06/14/2006 | EP1668110A2 Genetically modified somatic cells for sustained secretion of lysosomal proenzymes deficient in lysosomal storage disorders |
| 06/14/2006 | EP1668028A1 Antisense compound and method for selectively killing activated t cells |
| 06/14/2006 | EP1668024A2 Oligonucleotide compositions and methods for treating disease including inflammatory conditions |
| 06/14/2006 | EP1667763A1 Delivering genetic material to a stimulation site |
| 06/14/2006 | EP1667732A1 Biodegradable polyacetals for in vivo polynucleotide delivery |
| 06/14/2006 | EP1667731A1 Bispecific oligonucleotide for the treatment of cns malignancies |
| 06/14/2006 | EP1667730A2 Compositions and methods for treating inflammatory lung disease |
| 06/14/2006 | EP1667729A2 Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors |
| 06/14/2006 | EP1667728A1 Intravascular delivery of non-viral nucleic acid |
| 06/14/2006 | EP1667633A2 Polysaccharides for pulmonary delivery of active agents |
| 06/14/2006 | EP1667619A1 Pharmaceutical delivery system |
| 06/14/2006 | EP1667523A2 Dna vaccine compositions and methods of use |